What 8 Analyst Ratings Have To Say About Edwards Lifesciences
Over the past 3 months, 8 analysts have published their opinion on Edwards Lifesciences (NYSE:EW) stock. These analysts…
Morgan Stanley Maintains Overweight on Edwards Lifesciences, Raises Price Target to $95
Morgan Stanley analyst Cecilia Furlong maintains Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $92 to $95.
Jim Cramer Recommends These 5 Healthcare Stocks For 2023: ‘Biggest Winners Were Boring, Consistent Operators’
Prominent market commentator Jim Cramer has recommended five healthcare stocks which he believes should be on investors’ shopping list for 2023.
Raymond James Maintains Outperform on Edwards Lifesciences, Lowers Price Target to $83
Raymond James analyst Jayson Bedford maintains Edwards Lifesciences (NYSE:EW) with a Outperform and lowers the price target from $85 to $83.
Mizuho Maintains Buy on Edwards Lifesciences, Lowers Price Target to $85
Mizuho analyst Anthony Petrone maintains Edwards Lifesciences (NYSE:EW) with a Buy and lowers the price target from $100 to $85.
JPMorgan To Rally Around 17%? Here Are 10 Other Price Target Changes For Tuesday
Morgan Stanley raised JPMorgan Chase & Co. (NYSE:JPM) price target from $126 to $153. . Morgan Stanley analyst…
Stifel Downgrades Edwards Lifesciences to Hold, Lowers Price Target to $75
Stifel analyst Rick Wise downgrades Edwards Lifesciences (NYSE:EW) from Buy to Hold and lowers the price target from $95 to $75.
Wolfe Research Downgrades Edwards Lifesciences to Peer Perform
Wolfe Research analyst Mike Polark downgrades Edwards Lifesciences (NYSE:EW) from Outperform to Peer Perform.
Reata Pharmaceuticals To Jump 220%? Plus JP Morgan Predicts $51 For Las Vegas Sands
Goldman Sachs boosted the price target on Reata Pharmaceuticals, Inc. (NASDAQ: RETA) from $86 to $115. Goldman Sachs analyst Madhu Kumar maintained the stock with a Buy rating. Reata Pharmaceuticals shares rose 1.9% to close at $36.03 on Friday.
RBC Capital Maintains Outperform on Edwards Lifesciences, Lowers Price Target to $105
RBC Capital analyst Shagun Singh maintains Edwards Lifesciences (NYSE:EW) with a Outperform and lowers the price target from $118 to $105.